Jupiter Medical Center — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$62,150	2
2024	Research	$17,250	4
2021	Research	$22,733	7

Breakdown

Who paid Research payments · program years 2021–2025

Daiichi Sankyo Inc. $31,613 1 payment
AbbVie, Inc. $30,538 1 payment
Alexion Pharmaceuticals, Inc. $22,733 7 payments
Optellum Ltd $17,250 4 payments

Studies the money was for Research payments · program years 2021–2025

Ds8201-772 $31,613 1 payment
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer $30,538 1 payment
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome $22,733 7 payments
Before-After Operational Data Collection Study Protocol - Jupiter $17,250 4 payments

What the money was spent on Research payments · program years 2021–2025

Non-patient care $17,250 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.